A double-blind randomized phase II study on the efficacy of topical eye treatment
in the prevention of docetaxel-induced dacryostenosis.
Author(s): Leyssens B, Wildiers H, Lobelle JP, Gillis A, Paridaens R, Mombaerts I.
Affiliation(s): Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium.
barbara.leyssens@gmail.com
Publication date & source: 2010, Ann Oncol. , 21(2):419-23
BACKGROUND: Dacryostenosis is a common side-effect of weekly docetaxel
(Taxotere). We investigate the efficacy of eyedrops containing corticosteroids
(CS) versus artificial tears (AT) in patients receiving weekly docetaxel in the
prevention of dacryostenosis.
PATIENTS AND METHODS: Twenty patients receiving weekly docetaxel were evaluated.
Forty eyes were double-blind randomized: AT in one eye and CS in the other eye
were administered, six times daily, throughout the docetaxel administration.
Patients were assessed for tearing and stenosis at weeks 3, 6, 9 and 26. The
primary end point was the incidence of dacryostenosis in each group at 9 weeks.
RESULTS: At 9 weeks, punctal or canalicular stenosis was observed in 9 of 20
(45%) of the CS eyes and 9 of 20 (45%) of the AT eyes. Dacryostenosis was mild in
37 of 40 eyes (93%) and severe in 3 of 40 eyes (8%), with equal distribution in
the CS and AT group. Tearing was present in 9 of 20 (45%) of the CS eyes and 8 of
20 (40%) of the AT eyes, of which two eyes without stenosis in each group.
CONCLUSIONS: The incidence of dacryostenosis in patients receiving weekly
docetaxel was not different for the AT- and the CS-treated eyes. The
dacryostenosis was predominantly mild, not leading to surgical interventions.
|